Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
Ciardiello D, Napolitano S, Famiglietti V, Esposito L, De Falco V, Di Liello A, Avallone A, Maiello E, Pietrantonio F, Cremolini C, Zampino MG, Fazio N, Troiani T, Martinelli E, Ciardiello F, Martini G. Ciardiello D, et al. Cancers (Basel). 2023 Apr 1;15(7):2117. doi: 10.3390/cancers15072117. Cancers (Basel). 2023. PMID: 37046778 Free PMC article.
Clinical characteristics of critically ill patients with COVID-19.
Carboni Bisso I, Huespe I, Lockhart C, Massó A, Gonzalez Anaya J, Hornos M, Famiglietti R, Di Grazia M, Coria P, San Román E, Las Heras M. Carboni Bisso I, et al. Medicina (B Aires). 2021;81(4):527-535. Medicina (B Aires). 2021. PMID: 34453793 Free article. English.
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, Napolitano S, Esposito L, Latiano TP, Maiello E, Del Re M, Lonardi S, Aprile G, Santini D, Masi G, Avallone A, Normanno N, Pietrantonio F, Pinto C, Ciardiello F, Cremolini C, Martinelli E. Martini G, et al. Cancer Med. 2023 Apr;12(8):9392-9400. doi: 10.1002/cam4.5699. Epub 2023 Mar 7. Cancer Med. 2023. PMID: 36880426 Free PMC article.
Synthetic Versus Biological Mesh in Laparoscopic and Open Ventral Hernia Repair (LAPSIS): Results of a Multinational, Randomized, Controlled, and Double-blind Trial.
Miserez M, Lefering R, Famiglietti F, Mathes T, Seidel D, Sauerland S, Korolija D, Heiss M, Weber G, Agresta F, Steup WH, Śmietański M, Ribeiro R, Cuccurullo D, Catena F, Rudroff C, Rosanelli G, Schön F, Smet B, Wenger F, Saad S, Naver L, Neugebauer E. Miserez M, et al. Ann Surg. 2021 Jan 1;273(1):57-65. doi: 10.1097/SLA.0000000000004062. Ann Surg. 2021. PMID: 33332873 Clinical Trial.
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F. Orditura M, et al. Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4. Breast. 2018. PMID: 30103105